Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (2003)	1/6/2004 9:35:03 AM
From: Extra Pale	Read Replies (1) of 3044

(from yahoo board) Adam Feuerstein Millennium Pharma halts Velcade colon cancer study 1/06/04 08:44 AM ET Breaking news: Millennium Pharmaceuticals (MLNM-Nasdaq) has halted a study of its cancer drug Velcade in colon cancer patients, raising questions about the drug's ability to treat solid tumors. A Millennium spokeswoman confirms that the phase 2 Velcade study in colon cancer has been stopped, but she says the reason is for a pre-planned interim efficacy analysis. Results of this analysis will be made public next week when the company presents at the J.P. Morgan healthcare conference. But sources knowledgeable with this study tell me that, in fact, Velcade has proven to be ineffective as a colon cancer treatment. In other words, the study failed, which is why it was halted. Velcade is approved for multiple myeloma, a cancer of the blood, and is doing well commercially in this indication. But in order for Velcade to achieve blockbuster status, it must be approved and used in solid tumors like cancers of the colon, lung, etc. Millennium has been conducting a variety of early- and mid-stage studies of Velcade in solid tumors, of which the colon cancer study was one.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next